Lilly’s drug for Alzheimer’s fails big trial; shares drop

Eli Lilly's experimental drug failed to slow loss of cognitive ability in patients with mild Alzheimer's disease in a large trial, causing shares to tank.

INDIANAPOLIS (Reuters) – The failure of Eli Lilly and Co’s Alzheimer’s treatment to slow declines in mental capacity of patients with even mild symptoms cast serious doubt over whether a long-held approach to the memory-robbing disease could provide meaningful benefit to millions of people at risk.

The drug, solanezumab, failed to slow loss of cognitive ability in patients of mild Alzheimer’s disease, a major setback for patients, investors and the drug maker.